UNSPSC 51172316: Dimercaptosuccinic acid or succimer

This classification denotes a metal chelator with the molecular formula C4H6O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DX1U2629QE, chemically known as 2,3-dithio-meso-tartaric acid but generally known as succimer, which bears US NIH Compound Identifier 9354. European Medicines Agency schedules Succimer in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10663MIG.

The term SUCCIMER is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). SUCCIMER is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Dimercaptosuccinic acid or succimer bears US NLM identifiers UMLS ID C0012384 and NCI Concept Code C61953. SMILES: C(C(C(=O)O)S)(C(=O)O)S.

UNSPSC 51172316 Dimercaptosuccinic acid or succimer is a Commodity code covering a specific pharmaceutical active ingredient used primarily in chelation therapy for heavy metal poisoning. State and local governments procure this compound through two distinct channels: direct pharmaceutical purchasing for public health and clinical use, and inclusion within broader generic pharmaceutical and over-the-counter product procurement programs that serve multiple state and local agencies, educational institutions, and correctional systems. The issuing bodies span state health and human services departments, cooperative purchasing alliances serving multiple jurisdictions, and specialized county or city departments such as corrections and community supervision agencies.

Recent activity shows Texas and Minnesota leading current procurement momentum. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 (response deadline April 3, 2026) to explore direct-to-manufacturer prescription programs and vendor capabilities for implementing therapeutic pharmacy initiatives outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 (response deadline March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across multiple states including Oregon, with awarded vendors effective July 1, 2026. Collin County Community Supervision and Corrections Department in Texas issued RFP 2026-327 on July 9, 2026 (response deadline July 23, 2026) for offender specimen collection and drug testing services including immunoassay screening and confirmation testing with an estimated contract value of $600,000 over two years plus optional renewals. While the Collin County solicitation focuses on testing services rather than direct purchase of dimercaptosuccinic acid, the MMCAP and Texas HHS RFIs indicate active state-level interest in restructuring pharmaceutical procurement channels and expanding direct vendor relationships.